Evotec SE (Germany) Today
| EVT Stock | 8.83 0.24 2.65% |
Performance9 of 100
| Odds Of DistressLess than 33
|
Evotec SE is selling for under 8.83 as of the 2nd of December 2024; that is 2.65 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 8.75. Evotec SE has about a 33 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Evotec SE are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of December 2022 and ending today, the 2nd of December 2024. Click here to learn more.
Moving against Evotec Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Evotec Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Evotec SE's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Evotec SE or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers-Specialty & Generic, Healthcare (View all Sectors) |
Evotec SE (EVT) is traded on XETRA Stock Exchange in Germany and employs 4,715 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.94 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evotec SE's market, we take the total number of its shares issued and multiply it by Evotec SE's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Evotec SE operates under Healthcare sector and is part of Drug Manufacturers-Specialty & Generic industry. The entity has 176.95 M outstanding shares.
Evotec SE has accumulated about 699.33 M in cash with 122.24 M of positive cash flow from operations.
Check Evotec SE Probability Of Bankruptcy
Ownership AllocationEvotec SE holds a total of 176.95 Million outstanding shares. Over half of Evotec SE's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Evotec SE. Please watch out for any change in the institutional holdings of Evotec SE as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Evotec Ownership Details
Evotec SE Risk Profiles
Although Evotec SE's alpha and beta are two of the key measurements used to evaluate Evotec SE's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 4.0 | |||
| Semi Deviation | 4.65 | |||
| Standard Deviation | 5.94 | |||
| Variance | 35.27 |
Evotec Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Evotec SE without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Evotec SE Corporate Management
Elected by the shareholders, the Evotec SE's board of directors comprises two types of representatives: Evotec SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evotec. The board's role is to monitor Evotec SE's management team and ensure that shareholders' interests are well served. Evotec SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evotec SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthias Evers | Chief Board | Profile | |
| Volker Braun | VP ESG | Profile | |
| Cord Dohrmann | Chief Board | Profile | |
| Enno Spillner | CFO Board | Profile | |
| Monika Conradt | Global HR | Profile | |
| MBA MBA | Chairman CEO | Profile | |
| Christian Dargel | EVP Compliance | Profile |
Additional Tools for Evotec Stock Analysis
When running Evotec SE's price analysis, check to measure Evotec SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evotec SE is operating at the current time. Most of Evotec SE's value examination focuses on studying past and present price action to predict the probability of Evotec SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evotec SE's price. Additionally, you may evaluate how the addition of Evotec SE to your portfolios can decrease your overall portfolio volatility.